A drug used to target IDH1 mutations in select cancers also appears to inhibit the wild-type form of the enzyme, under certain conditions. This feature explains why a large group of different cancers ...
The FDA approved vorasidenib (Voranigo) for patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. The drug -- an IDH1 and IDH2 inhibitor - ...
The Food and Drug Administration (FDA) has approved ivosidenib (Tibsovo) for the treatment of adults with previously treated locally advanced or metastatic IDH1-mutated cholangiocarcinoma (CCA), a ...
A Targeted Methylation–Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease This retrospective analysis ...
Ivosidenib plus azacitidine significantly prolongs median overall survival in patients with IDH1-mutated acute myeloid leukemia (AML), with a median overall survival of 29.3 months versus 7.9 months ...
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has described isocitrate dehydrogenase (NADP) cytoplasmic (IDH1; PICD; IDP) (mutant) inhibitors reported to be useful for the ...
A research team in Japan has developed an innovative system that can accurately detect genetic mutations in the brain tumor within just 25 minutes. Genetic mutations are crucial markers for diagnosis ...
“We saw really quite remarkable outcomes in a very high-risk MDS population, not only in response rates, but also in blood count improvement, long duration of response and improved overall survival,” ...
The FDA has approved Voranigo to treat certain patients with grade 2 astrocytoma or oligodendroglioma with select mutations, following surgery. The Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results